Literature DB >> 9733047

PTEN and prostate cancer.

E A Facher, J C Law.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9733047      PMCID： PMC1051444          DOI： 10.1136/jmg.35.9.790-a

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  8 in total

1.  PTEN1 is frequently mutated in primary endometrial carcinomas.

Authors:  D Kong; A Suzuki; T T Zou; A Sakurada; L W Kemp; S Wakatsuki; T Yokoyama; H Yamakawa; T Furukawa; M Sato; N Ohuchi; S Sato; J Yin; S Wang; J M Abraham; R F Souza; K N Smolinski; S J Meltzer; A Horii
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

2.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Authors:  H Tashiro; M S Blazes; R Wu; K R Cho; S Bose; S I Wang; J Li; R Parsons; L H Ellenson
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

5.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

6.  Cowden disease: gene marker studies and measurements of epidermal growth factor.

Authors:  H E Carlson; T W Burns; S L Davenport; A M Luger; M A Spence; R S Sparkes; D N Orth
Journal:  Am J Hum Genet       Date:  1986-06       Impact factor: 11.025

7.  Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy?

Authors:  C Eng; V Murday; S Seal; S Mohammed; S V Hodgson; M A Chaudary; I S Fentiman; B A Ponder; R A Eeles
Journal:  J Med Genet       Date:  1994-06       Impact factor: 6.318

8.  The Cowden syndrome: a clinical and genetic study in 21 patients.

Authors:  T M Starink; J P van der Veen; F Arwert; L P de Waal; G G de Lange; J J Gille; A W Eriksson
Journal:  Clin Genet       Date:  1986-03       Impact factor: 4.438
  8 in total
  6 in total

1.  Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Authors:  Myles C Hodgson; Long-jiang Shao; Anna Frolov; Rile Li; Leif E Peterson; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

Review 2.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

3.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.

Authors:  B Kwabi-Addo; D Giri; K Schmidt; K Podsypanina; R Parsons; N Greenberg; M Ittmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 4.  Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

5.  Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.

Authors:  Tarek A Bismar; Samar Hegazy; Zhaoyong Feng; Darryl Yu; Bryan Donnelly; Nallasivam Palanisamy; Bruce J Trock
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-12       Impact factor: 4.553

6.  Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.

Authors:  K M Dixon; G Y L Lui; Z Kovacevic; D Zhang; M Yao; Z Chen; Q Dong; S J Assinder; D R Richardson
Journal:  Br J Cancer       Date:  2013-01-03       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.